Abstract:Background Systemic sclerosis (SSc) is a connective tissue disease characterized by autoimmunity, small vessel vasculopathy and excessive collagen deposition in the skin and internal organs. Pulmonary involvement is responsible for reducing the functional capacity to exercise and represents the main cause of death. The six-minute walk test (6MWT) is a simple, non-invasive, easy-to-perform, and reliable submaximal aerobic exercise test that can used in patients with advanced lung disease. Patients with SSc often have not only lung disease, but combinations of cardiopulmonary involvement, skin fibrosis, musculoskeletal damage, and joint disease, which can confound the 6MWT interpretation. As it is an independent predictor of SSc-related mortality, the 6MWT is a potentially useful tool in the assessment of outcomes along with pulmonary function tests (PFTs) and computed tomography. Currently, there is a huge concern about the need for early screening, search for new treatments and closer monitoring of patients with diffuse cutaneous systemic sclerosis-associated interstitial lung disease (dcSSs-ILD) before irreversible deterioration of lung function occurs. Objectives To build a predictive model for the six-minute walk distance (6MWD) in women with dcSSs-ILD without pulmonary arterial hypertension. Methods This is a cross-sectional study in which 69 women with dcSSs-ILD underwent the 6MWT, Health Assessment Questionnaire-Disability Index (HAQ-DI), PFTs (including spirometry, measurement of pulmonary diffusion capacity for carbon monoxide-DLCO and measurement of respiratory muscle strength), handgrip strength (HGS) and quadriceps strength (QS). Results The mean 6MWD was 447 ± 78 m, with 43.5% of the participants not reaching 80% of the predicted value. The 6MWT was positively correlated with HR (r = 0.418, P = 0.0004), forced vital capacity (r = 0.306, P = 0.011), DLCO (r = 0.360, P = 0.002), maximal inspiratory pressure (r = 0.268 , P = 0.029), and maximal expiratory pressure (MEP, r = 0.288, P = 0.019) and negatively with age (r = -0.378, P = 0.001), body mass index (BMI) r = -0.248, P = 0.039) and HAQ-DI (r = -0.438, P = 0.0001). In the multiple linear regression analysis, QS, BMI, DLCO, age and MEP explained 72% of the 6MWD variability. Conclusion In patients with dcSSs-ILD, alongside reduced pulmonary diffusion, deterioration in respiratory and peripheral muscle strength negatively impact performance during the 6MWT. Furthermore, the greater the age and BMI, the lower the 6MWD. Our results are promising and may become a contribution to future investigations aimed at new pharmacological therapies for dcSSs-ILD. Implications These findings may help the growing number of randomized controlled trials that have emerged in search of disease-modifying therapies for dcSSs-ILD, with the aim of incorporating the 6MWD as a clinical outcome measure.

Use of 6‐minute walk distance to predict lung transplant‐free survival in fibrosing non‐IPF interstitial lung diseases

Use of 6-min walk distance to predict lung transplant-free survival in fibrosing non-IPF interstitial lung diseases

Percent Predicted vs. Absolute Six-Minute Walk Distance as Predictors of Lung Transplant-Free Survival in Fibrosing Interstitial Lung Diseases

Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis

Clinical implications of six-minute walk test in patients with idiopathic pulmonary fibrosis: a retrospective cohort study

Use of 6-Minute Walk Test for Assessing Severity of Interstitial Lung Disease: an Observational Study.

Features and predictive value of 6-min walk test outcomes in interstitial lung disease: an observation study using wearable monitors

Incremental prognostic value of functional impairment assessed by 6-min walking test for the prediction of mortality in heart failure

Lung function trajectory in progressive fibrosing interstitial lung disease

Functional limitation predicts mortality in heart failure with preserved ejection fraction

Detection of Idiopathic Pulmonary Fibrosis Disease Progression using Respiratory Oscillometry

VARIABILITY OF 6-MINUTE WALK DISTANCE IN PATIENTS WITH INTERSTITIAL LUNG DISEASE ASSOCIATED WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS

The 6-min walking distance: long-term follow up in patients with COPD

Associations between 6-minute walk distance and physiologic measures and clinical outcomes in myositis-associated interstitial lung disease

Prediction of Poor Short-Term Prognosis and Unmet Needs in Advanced Chronic Obstructive Pulmonary Disease: Use of the Two-Minute Walking Distance Extracted from a Six-Minute Walk Test

Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study

Association Between Functional Tests and Mortality in Patients with Interstitial Lung Disease

Pursuing Clinical Predictors and Biomarkers for Progression in ILD: Analysis of the Pulmonary Fibrosis Foundation (PFF) Registry

Feasibility of the Six-Minute Walk Test for Patients Who Have Cystic Fibrosis, Are Ambulatory, and Require Mechanical Ventilation Before Lung Transplantation

Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort

Six‐minute walking distance and desaturation–distance ratio in allogeneic stem cell transplantation